Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC”) reaches 1,003 of 1,224 ...
Analysts expect S&P 500 companies overall to have increased earnings by 9.6% in the fourth quarter of 2024 compared with the ...
The S&P 500 Index (SPX) generated “unusually strong” return during the first three quarters of 2024 – compared to the ...
58mon MSN
TD SYNNEX (NYSE:SNX) is scheduled to announce Q4 earnings results on Friday, January 10th, before market open. The consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback